- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Molecular Partners AG ADR (MOLN)
Molecular Partners AG ADR stock price live, this page displays NASDAQ MOLN stock exchange data. View the MOLN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Molecular Partners AG ADR real time stock price chart below.
What Is the Molecular Partners AG ADR Stock Price Today?
The Molecular Partners AG ADR stock price today is 4.350.
What Is the Stock Symbol for Molecular Partners AG ADR?
The stock symbol for Molecular Partners AG ADR is "MOLN."
What Stock Exchange Does Molecular Partners AG ADR Trade On?
Molecular Partners AG ADR is listed and trades on the NASDAQ stock exchange.
Is Molecular Partners AG ADR a Good Stock to Buy?
Determining whether Molecular Partners AG ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MOLN quote. (ISIN: US60853G1067)
What Is the Molecular Partners AG ADR Stock Price Today?
The Molecular Partners AG ADR stock price today is 4.350.
What Is the Stock Symbol for Molecular Partners AG ADR?
The stock symbol for Molecular Partners AG ADR is "MOLN."
What Stock Exchange Does Molecular Partners AG ADR Trade On?
Molecular Partners AG ADR is listed and trades on the NASDAQ stock exchange.
Is Molecular Partners AG ADR a Good Stock to Buy?
Determining whether Molecular Partners AG ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MOLN quote. (ISIN: US60853G1067)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.350
4.350
52 wk Range
3.530
5.360
MOLN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.3504.350
52 wk Range
3.5305.360
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
MOLN Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
10.648
Upside
+144.79%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Form 6K Molecular Partners AG ADR For: 1 May- Investing.com
Form 6K Molecular Partners AG ADR For: 1 June- Investing.com
Form 6K Molecular Partners AG ADR For: 12 May- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Strong Buy
Analyst Ratings
4 Buy
1 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 10.648
(+144.79% Upside)
Earnings
Latest Release
Aug 25, 2026
EPS / Forecast
-0.44 / -0.44
Revenue / Forecast
-- / --
Compare MOLN to Peers and Sector
Metrics to compare | MOLN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMOLNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.6x | −0.1x | −0.4x | |
PEG Ratio | −0.11 | 0.00 | 0.00 | |
Price/Book | 2.3x | 2.0x | 2.6x | |
Price / LTM Sales | - | 3.1x | 3.1x | |
Upside (Analyst Target) | 173.7% | 68.3% | 49.6% | |
Fair Value Upside | Unlock | 6.5% | 7.1% | Unlock |
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Molecular Partners AG (MOLN) Stock Price Today?
The Molecular Partners AG stock price today is 4.350 USD.
What Stock Exchange Does Molecular Partners AG Trade On?
Molecular Partners AG is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Molecular Partners AG?
The stock symbol for Molecular Partners AG is "MOLN."
What Is the Molecular Partners AG Market Cap?
As of today, Molecular Partners AG market cap is 166.030M USD.
What Is Molecular Partners AG's Earnings Per Share (TTM)?
The Molecular Partners AG EPS (TTM) is -1.359.
When Is the Next Molecular Partners AG Earnings Date?
Molecular Partners AG will release its next earnings report on Oct 29, 2026.
From a Technical Analysis Perspective, Is MOLN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Molecular Partners AG Stock Split?
Molecular Partners AG has split 0 times.
How Many Employees Does Molecular Partners AG Have?
Molecular Partners AG has 134 employees.
What is the current trading status of Molecular Partners AG (MOLN)?
As of Sep 04, 2026, Molecular Partners AG (MOLN) is trading at a price of 4.350 USD, with a previous close of 4.070 USD. The stock has fluctuated within a day range of 4.350 USD to 4.350 USD, while its 52-week range spans from 3.530 USD to 5.360 USD.
What Is Molecular Partners AG (MOLN) Price Target According to Analysts?
The average 12-month price target for Molecular Partners AG is 10.648 USD, with a high estimate of 16.8207024 USD and a low estimate of 3.73505853 USD. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +144.79% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.